He is an ex-hedge fund manager whose previous biotech company ousted him amid allegations he was using the company to pay off his debts from a previous hedge fund. A fund that got sued by Lehman Brothers for $2.3m - although they conveniently ceased to exist before that could be enforced.
He is all about short term decisions and fucking every body else.
The Beeb reports £1.15bn to bring a drug to market, with only 10% of that being the actual costs of R&D and the clinical trials.
http://www.bbc.co.uk/news/health-27130098
Most of the cost is the cost of capital - pay back is in the decades time frame. This does of course beg the question of if they are gouging profits in the short term, why are they paying exorbitant amounts to borrow money for R&D? That 10% figure is shocking.
This CEO's particular history aside, i'm still not convinced profiteering is at the heart of the matter. As you say, COC is a large factor, as is R&D. The COC is so high because blockbuster drugs are an uncertain commodity. It's almost a speculative business. You can go years down the development of a drug only for it to fail fundamentally or at a regulatory stage.
For me (speculation on my part) the price increase, which is US exclusive, comes down to moral hazard. Specifically Medicare is at fault. It makes sense, as the free medicine will likely go to those uninsured by the program, meaning the Medicare insurance system takes the financial hit. Granted, the consumer will feel the hit through increased premiums. Essentially, now that there is an insurance middle-man, moral hazard theory indicates that people don't really care as much about the price because a third party (the insurance companies) is taking the bulk of the cost increase. The pharmaceutical companies see an opportunity to tap into larger revenue streams and are likely competing for the next blockbuster with that revenue.
The poor generic market in the US is also behind this pricing; although this is somewhat of a calculated cost as the US are (rightly in my opinion) protective of their innovator centric pharmaceutical sector.